Q&A: Pfizer's Dx Division Head Discusses Pharma Giant's Focus on Personalized Medicine | GenomeWeb

By Turna Ray

Smaller diagnostics shops should not feel discouraged to bring their proposals to Pfizer because the pharma giant decided to partner with Abbott Molecular to develop a companion diagnostic for an investigational lung cancer drug, according to Hakan Sakul, the head of diagnostics at Pfizer's global R&D division.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.